目前,几乎所有抗肿瘤的药物和非药物治疗方法都可直接造成心脏和血管损伤,且恶性肿瘤与心血管疾病常伴有共同的危险因素,故心血管疾病已成为老年肿瘤患者致死的重要原因,严重恶化患者预后。2022年8月26日,在巴塞罗那举行的欧洲心脏病学...目前,几乎所有抗肿瘤的药物和非药物治疗方法都可直接造成心脏和血管损伤,且恶性肿瘤与心血管疾病常伴有共同的危险因素,故心血管疾病已成为老年肿瘤患者致死的重要原因,严重恶化患者预后。2022年8月26日,在巴塞罗那举行的欧洲心脏病学会(European Society of Cardiology,ESC)年会上,首部肿瘤心脏病学指南隆重发布,该指南由ESC联合欧洲血液病协会(European Hematology Association,EHA)。展开更多
There have been considerable advancements in cancer therapy in recent years. However, adverse effects often defeat the benefits, especially on the cardiovascular system. The effects of chemotherapeutic agents on the c...There have been considerable advancements in cancer therapy in recent years. However, adverse effects often defeat the benefits, especially on the cardiovascular system. The effects of chemotherapeutic agents on the cardiovascular system can be directly on the heart by altering the coagulability state or by altering the hemodynamic system. Some drugs like Sunitinib and Bevacizumab show Heart Failure which is chemotherapy-induced. Other agents are notorious for showing QT prolongation like Vandetanib. Similarly, other agents with demonstrated cardiotoxicity would be molecular-targeted drugs (Trastuzumab and Pertuzumab) and cytostatic agents (Anthracycline antibiotics, Cyclophosphamide and 5-FU). These effects may present early or late, during or after the treatment. Most of the research has focused on the management and monitoring of patients for cancer who are under treatment, for example new biomarkers in the field of proteomics have been discovered for the diagnosis, treatment, and monitoring of patients. While the upgrades have been successful in reducing mortalities, with the advent of better treatment outcomes, the several adverse effects on the cardiac system cannot be dismissed. For instance, damage to the cardiomyocytes is most frequently associated with the treatment. The damage can further expedite LV failure, valvular dysfunction, conduction abnormalities, etc. Hence, a better management plan for patients with cancer would be one that not only caters to primary cancer treatment but also incorporates ventricular systolic function evaluation using echocardiography, electrocardiography, and cardiac biomarkers for the well-being of patients. Our article focuses on introducing an ideal cardio-oncology team along with the components required for setting up the team. This needs a multidisciplinary approach to reduce patients’ cardiovascular morbidity, during and after the interventions. With the growing population of patients undergoing cancer therapy, the risk of developing cardiovascular problems has furt展开更多
Therapy development for cancer and cardiovascular disease(CVD)to prolong lifespan makes the relationship between these two conditions more complex.Drug interactions in cardiology and oncology are associated with metab...Therapy development for cancer and cardiovascular disease(CVD)to prolong lifespan makes the relationship between these two conditions more complex.Drug interactions in cardiology and oncology are associated with metabolism and drug transportation.Advances in biomarkers and imaging provide novel methods for detecting cardiotoxicity,including cardiac injury and inflammation.The new concept of CVD-related cancer risk is leading to a new direction of progression termed“reverse cardio-oncology.”展开更多
文摘目前,几乎所有抗肿瘤的药物和非药物治疗方法都可直接造成心脏和血管损伤,且恶性肿瘤与心血管疾病常伴有共同的危险因素,故心血管疾病已成为老年肿瘤患者致死的重要原因,严重恶化患者预后。2022年8月26日,在巴塞罗那举行的欧洲心脏病学会(European Society of Cardiology,ESC)年会上,首部肿瘤心脏病学指南隆重发布,该指南由ESC联合欧洲血液病协会(European Hematology Association,EHA)。
文摘There have been considerable advancements in cancer therapy in recent years. However, adverse effects often defeat the benefits, especially on the cardiovascular system. The effects of chemotherapeutic agents on the cardiovascular system can be directly on the heart by altering the coagulability state or by altering the hemodynamic system. Some drugs like Sunitinib and Bevacizumab show Heart Failure which is chemotherapy-induced. Other agents are notorious for showing QT prolongation like Vandetanib. Similarly, other agents with demonstrated cardiotoxicity would be molecular-targeted drugs (Trastuzumab and Pertuzumab) and cytostatic agents (Anthracycline antibiotics, Cyclophosphamide and 5-FU). These effects may present early or late, during or after the treatment. Most of the research has focused on the management and monitoring of patients for cancer who are under treatment, for example new biomarkers in the field of proteomics have been discovered for the diagnosis, treatment, and monitoring of patients. While the upgrades have been successful in reducing mortalities, with the advent of better treatment outcomes, the several adverse effects on the cardiac system cannot be dismissed. For instance, damage to the cardiomyocytes is most frequently associated with the treatment. The damage can further expedite LV failure, valvular dysfunction, conduction abnormalities, etc. Hence, a better management plan for patients with cancer would be one that not only caters to primary cancer treatment but also incorporates ventricular systolic function evaluation using echocardiography, electrocardiography, and cardiac biomarkers for the well-being of patients. Our article focuses on introducing an ideal cardio-oncology team along with the components required for setting up the team. This needs a multidisciplinary approach to reduce patients’ cardiovascular morbidity, during and after the interventions. With the growing population of patients undergoing cancer therapy, the risk of developing cardiovascular problems has furt
文摘Therapy development for cancer and cardiovascular disease(CVD)to prolong lifespan makes the relationship between these two conditions more complex.Drug interactions in cardiology and oncology are associated with metabolism and drug transportation.Advances in biomarkers and imaging provide novel methods for detecting cardiotoxicity,including cardiac injury and inflammation.The new concept of CVD-related cancer risk is leading to a new direction of progression termed“reverse cardio-oncology.”
